D. Boral Capital Reiterates "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)

D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock.

A number of other brokerages have also weighed in on CNTX. Citizens Jmp upgraded shares of Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. William Blair started coverage on Context Therapeutics in a research note on Monday, April 21st. They set an "outperform" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Context Therapeutics in a report on Friday, March 21st. Finally, JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $6.17.

Context Therapeutics Stock Up 0.8 %

Shares of CNTX stock traded up $0.01 during mid-day trading on Tuesday, reaching $0.87. 30,000 shares of the company's stock traded hands, compared to its average volume of 303,796. The company's 50-day moving average price is $0.78 and its 200-day moving average price is $1.18. The company has a market cap of $78.01 million, a P/E ratio of -0.96 and a beta of 2.18. Context Therapeutics has a 12 month low of $0.55 and a 12 month high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. Equities analysts predict that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Trading of Context Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Context Therapeutics during the 4th quarter valued at about $29,000. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at $31,000. Shay Capital LLC acquired a new stake in Context Therapeutics in the fourth quarter worth about $52,000. Clear Harbor Asset Management LLC grew its position in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after purchasing an additional 21,804 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Context Therapeutics during the fourth quarter valued at $94,000. Institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.